Hrt Financial LP Genmab A/S Transaction History

Hrt Financial LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$25.13 - $30.27 $260,120 - $313,324	10,351 New	10,351 $260,000
Q3 2023 Nov 13, 2023	BUY	$35.27 - $42.24 $250,840 - $300,410	7,112 New	7,112 $250,000
Q1 2022 May 16, 2022	SELL	$30.95 - $39.68 $1.85 Million - $2.38 Million	-59,893 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$35.87 - $47.12 $2.15 Million - $2.82 Million	59,893 New	59,893 $2.37 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.